

# DIAGNOSTIC TARGET PRODUCT PROFILES

for monitoring, evaluation and surveillance of schistosomiasis control programmes



# DIAGNOSTIC TARGET PRODUCT PROFILES for monitoring, evaluation and surveillance of

schistosomiasis control programmes



Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes

ISBN 978-92-4-003110-4 (electronic version) ISBN 978-92-4-003111-1 (print version)

#### © World Health Organization 2021.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers**. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

### Contents

| Acknowledgements |  | iv |
|------------------|--|----|
| 1.               | Introduction   | 1  |
| 2.               | Epidemiology   | 1  |
| 3.               | Public health response   | 1  |
| 4.               | Available diagnostic tools   | 2  |
| 5.               | Diagnostic Technical Advisory Group  | 3  |
| 6.               | Purpose of the target product profile  | 3  |
|                  | 6.1. TPP for Monitoring and Evaluation   | 3  |
|                  | 6.2. TPP for transmission interruption and subsequent surveillance                       | 3  |
| 7.               | Characteristics of a needed diagnostic test for Schistosomiasis to support               |    |
|                  | Monitoring and Evaluation  | 5  |
| 8.               | Characteristics of a needed diagnostic test for Schistosomiasis to support decisions for |    |
|                  | transmission interruption and subsequent surveillance                                    | 12 |
| Re               | References   |    |

## Acknowledgements

These WHO target product profiles (TPP) were developed under the direction of the Department of Control of Neglected Tropical Diseases following standard WHO guidance for TPP development. Special thanks are due to members of the Diagnostic Technical Advisory Group for Neglected Tropical Diseases' Subgroup on Schistosomiasis: Fiona Fleming, Eyrun Floerecke Kjetland, Hanan Gamal El Baz, Chris Hanna, Martin Johannes Enk, Charles King, Bruno Levecke, Francisca Mutapi, Sarah Nogaro, Maurice Odiere, Hiroshi Omae and William E. Secor (chair).

Thanks are due to Camilla Ducker and Ashley Souza for organizational support to subgroup meetings; Patrick Lammie (chair) and members of the Diagnostic Technical Advisory Group for guidance; and members of the neglected tropical disease (NTD) community and the general public for feedback on the draft TPPs. WHO staff members Daniel Argaw Dagne, Amadou Garba Djirmay, Jonathan King, Antonio Montresor, Denise Mupfasoni, Pauline Mwinzi, Bernadette Ramirez, Ronaldo Scholte, Anthony Solomon and Aya Yajima gave support and input to the TPP development process.

Funding support for the development of these TPPs was provided by the Bill & Melinda Gates Foundation and the United States Agency for International Development.

## 1. Introduction

Schistosomiasis is a parasitic disease of 240 million people globally (1). Infection occurs when people come into contact with contaminated water populated with the appropriate intermediate host snail. Larval parasites penetrate the skin and enter the body where they mature into adult male and female worms, mate and produce eggs. Some eggs released by adult females exit the body to continue the parasite's life cycle; other eggs become trapped in host tissues where they stimulate immunological responses that cause the morbidity associated with schistosomiasis.

# 2. Epidemiology

Human schistosomiasis, also known as bilharzia or "snail fever", is caused by five main species of trematodes of the genus *Schistosoma*. Approximately 90% of infections and the vast majority of morbidity occur in sub-Saharan Africa, where the two primary species responsible for human disease are *S. mansoni* and *S. haematobium*. Adult *S. mansoni* worms live in the mesenteric veins surrounding the intestines. To complete the life cycle, eggs must make their way to the lumen of the gut where they are excreted in host faeces. However, many eggs are washed by the portal circulation to the liver where they become trapped and stimulate granulomatous responses. Over time, untreated schistosomiasis can stimulate fibrosis of the liver and increased portal pressure, resulting in liver and spleen enlargement. In the most severe cases, ascites and oesophageal varices develop and can lead to haematemesis and death. Asian schistosomiasis caused by *S. japonicum* and *S. mekongi* has clinical manifestations like those of *S. mansoni* (2).

*S. haematobium* adult worms live in the blood vessels surrounding the bladder; eggs are excreted in the urine, resulting in haematuria which can be microscopic or visual. Chronic infection can result in bladder fibrosis with obstructive uropathy and is associated with increased risk of squamous cell carcinoma of the bladder. Worms in the venous plexus can also result in egg deposition in genital tissues, causing female and male genital schistosomiasis, which is associated with greater risk of HIV transmission (*3*). These severe morbidities tend to affect older individuals who have been infected for several years. However, the bulk of the more than 1.6 million disability-adjusted life years (*4*) caused by schistosomiasis worldwide affect children, who have the highest prevalence and intensity of infections. Morbidities in children include anaemia, delays in physical and cognitive development, and reduced tolerance to exercise (*2*).

### 3. Public health response

Because the prevalence and intensity of infection peaks at 7–15 years of age, the main strategy for control of schistosomiasis focuses on mass drug administration (MDA) of praziquantel, in priority to primary school-aged children. Praziquantel is safe for people who do not have infections, and it is more cost-effective to treat all school-aged children in a community above a certain prevalence threshold than to test and treat each individual. MDA is typically administered by control programmes in areas endemic for schistosomiasis once each year. However, MDA is not enough to interrupt transmission without additional measures such as increased access to clean water and sanitation, control of intermediate host snails, or education and behavioural change. As a result, WHO guidelines for most countries target control and then elimination of morbidity.

In general, higher intensities of infection are associated with higher levels of morbidity, but these relationships are poorly defined, and most control programmes monitor only prevalence of infection and not intensity (5). Research is under way to better define the relationship between prevalence, intensity of infection and various manifestations of morbidity; for the time being, the working guidance for control programmes is to administer MDA annually in communities with  $\geq 10\%$  prevalence among primary school-aged children (6). Because distribution of schistosomiasis is highly focal, implementation decisions are applied at the subdistrict level. Operational research is required to determine the frequency and design of epidemiological assessments to measure the impact of schistosomiasis programmes and support decision-making aligned to the focality of infection as well as determining persistent hotspots of transmission where community levels of infection are not responding to current MDA intervention.

#### 4. Available diagnostic tools

Traditionally, schistosomiasis has been diagnosed by detecting parasite eggs in host stool (*S. mansoni S. mekongi, S. japonicum*) or urine (*S. haematobium*) (*7*). These methods have the advantage of providing information on both prevalence and intensity of infection and, theoretically, they can distinguish active infection from successful cure and/or subsequent reinfection. However, it is sometimes difficult to obtain samples for egg detection methods, their sensitivity for low intensity infections is poor, and they require access to microscopes and trained personnel. Usually, samples are processed in a laboratory distant from the site.

Circulating cathodic antigen (CCA) is regurgitated from the blind gut of schistosomes, cleared by the patient's kidneys and excreted in the urine. Like eggs, urinary CCA disappears after successful cure and resumes after reinfection. It also provides a relative intensity of infection and is considered much more sensitive than egg detection. A point-of-care CCA test is commercially available. Unfortunately, current formulations of the test are reliable only in high-prevalence areas and the false-positivity rate is too high to accurately determine prevalence < 10% (8). Furthermore, recent manufacturing issues have yielded product lots of variable performance and very high false-positive rates (9, 10). Even when working well, the point-of-care CCA test is much more effective at detecting *S. mansoni* infections than other schistosomiasis species infections (11, 12).

Like CCA, circulating anodic antigen is also detectable in an infected host's blood or urine, is a marker for active infection, provides information on relative intensity of infection and has the added advantage of being produced in detectable amounts by both *S. mansoni* and *S. haematobium (13)*. However, it is not available as a commercial test, and current developmental tests require laboratory equipment for sample concentration and final test readout. Polymerase chain reaction to detect parasite DNA in stool

# 预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 23629